MCID: PLM014
MIFTS: 56

Pleomorphic Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Pleomorphic Adenoma

MalaCards integrated aliases for Pleomorphic Adenoma:

Name: Pleomorphic Adenoma 12 15
Mixed Tumor of the Salivary Gland 12 17
Mixed Tumor, Not Otherwise Specified 74
Mixed Salivary Gland Tumor 74
Adenoma, Pleomorphic 45
Adenoma Pleomorphic 56

Classifications:



External Ids:

Disease Ontology 12 DOID:452
MeSH 45 D008949
NCIt 51 C35691 C8602
SNOMED-CT 69 8360001

Summaries for Pleomorphic Adenoma

Disease Ontology : 12 A gastrointestinal system benign neoplasm that is a located in the salivary glands.

MalaCards based summary : Pleomorphic Adenoma, also known as mixed tumor of the salivary gland, is related to pleomorphic adenoma carcinoma and salivary gland adenoma, pleomorphic. An important gene associated with Pleomorphic Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Development EGFR signaling pathway and DNA Damage. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, bone and uterus, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Pleomorphic adenoma is a common benign salivary gland neoplasm characterised by neoplastic proliferation... more...

Related Diseases for Pleomorphic Adenoma

Diseases related to Pleomorphic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 pleomorphic adenoma carcinoma 34.3 ERBB2 HMGA2 TP53
2 salivary gland adenoma, pleomorphic 33.4 HMGA2 PLAG1 S100B
3 adenoma 32.3 PLAG1 PLAGL1 PLAGL2 TP53
4 epithelial-myoepithelial carcinoma 30.9 HMGA2 KRT14 TP53
5 neurilemmoma 30.9 GFAP S100B VIM
6 pleomorphic lipoma 30.7 HMGA2 MDM2
7 mucoepidermoid carcinoma 30.7 ERBB2 KRT14 MUC1 TP63
8 nodular hidradenoma 30.5 MUC1 VIM
9 carcinosarcoma 30.4 ACTC1 ERBB2 MUC1 TP53 VIM
10 chordoma 30.3 GFAP MUC1 S100B VIM
11 pyogenic granuloma 30.2 ACTC1 TP63
12 spindle cell lipoma 30.1 ACTC1 MDM2 VIM
13 giant cell tumor 30.1 ACTC1 MUC1 VIM
14 in situ carcinoma 30.1 ERBB2 KRT14 TP53
15 mesenchymoma 30.1 HMGA2 MDM2
16 leiomyoma 30.0 ACTC1 HMGA2 VIM
17 myxoid liposarcoma 30.0 HMGA2 MDM2 TP53
18 liposarcoma 29.9 HMGA2 MDM2 TP53 VIM
19 rhabdomyosarcoma 29.7 ACTC1 MDM2 TP53 VIM
20 hemangiopericytoma, malignant 29.7 ACTC1 MDM2 MUC1 S100B VIM
21 syringoma 29.6 GFAP MUC1 S100B SERPINB5 TP63 VIM
22 polymorphous low-grade adenocarcinoma 29.6 ACTC1 MUC1 S100B SERPINB5 TP63 VIM
23 leiomyosarcoma 29.5 ACTC1 MDM2 S100B TP53 VIM
24 myoepithelioma 29.5 ACTC1 GFAP KRT14 S100B SERPINB5 TP63
25 adenoid cystic carcinoma 29.4 ACTC1 ERBB2 KRT14 MUC1 S100B SERPINB5
26 mixed lacrimal gland cancer 11.7
27 myoepithelial carcinoma 10.6
28 adenocarcinoma 10.6
29 scrotal carcinoma 10.5 HMGA2 TP53
30 astroblastoma 10.5 GFAP VIM
31 central nervous system primitive neuroectodermal neoplasm 10.5 GFAP TP53
32 cerebral neuroblastoma 10.5 GFAP TP53
33 mixed glioma 10.5 GFAP TP53
34 spinal cancer 10.5 GFAP TP53
35 endometrial mucinous adenocarcinoma 10.5 MUC1 VIM
36 biphasic synovial sarcoma 10.5 MUC1 VIM
37 dysembryoplastic neuroepithelial tumor 10.5 GFAP S100B
38 uterine corpus serous adenocarcinoma 10.5 ERBB2 TP53
39 non-proliferative fibrocystic change of the breast 10.5 ERBB2 TP53
40 aggressive digital papillary adenocarcinoma 10.5 MUC1 S100B
41 frontal convexity meningioma 10.4 GFAP TP53
42 hard palate cancer 10.4
43 gliofibroma 10.4 GFAP TP53
44 hydromyelia 10.4 S100B VIM
45 localized hypertrophic neuropathy 10.4 MUC1 S100B
46 sclerosing perineurioma 10.4 MUC1 S100B
47 benign metastasizing leiomyoma 10.4 ACTC1 VIM
48 primitive neuroectodermal tumor of the cervix uteri 10.4 GFAP VIM
49 bednar tumor 10.4 S100B VIM
50 cerebral convexity meningioma 10.4 GFAP TP53

Graphical network of the top 20 diseases related to Pleomorphic Adenoma:



Diseases related to Pleomorphic Adenoma

Symptoms & Phenotypes for Pleomorphic Adenoma

GenomeRNAi Phenotypes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

27 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 S100B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.84 VIM
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.84 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 PLAG1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.84 PLAGL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.84 PLAGL2 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.84 PLAG1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.84 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.84 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.84 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.84 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.84 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.84 VIM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.84 ERBB2 PLAG1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.84 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.84 PLAG1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 ERBB2 PLAG1 PLAGL2 S100B VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 PLAGL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 PLAGL2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 ERBB2 S100B VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 PLAG1

MGI Mouse Phenotypes related to Pleomorphic Adenoma:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 ACTC1 AR ERBB2 GFAP KRT14 MDM2
2 growth/size/body region MP:0005378 10.23 ACTC1 AR ERBB2 GFAP KRT14 MDM2
3 cardiovascular system MP:0005385 10.22 ACTC1 AR ERBB2 GFAP MDM2 MYOZ2
4 homeostasis/metabolism MP:0005376 10.21 ACTC1 AR ERBB2 GFAP KRT14 MDM2
5 embryo MP:0005380 10.13 AR ERBB2 MDM2 PLAG1 PLAGL1 SERPINB5
6 mortality/aging MP:0010768 10.13 ACTC1 AR ERBB2 GFAP KRT14 MDM2
7 digestive/alimentary MP:0005381 10.1 AR ERBB2 GFAP KRT14 MDM2 PLAGL2
8 integument MP:0010771 10.01 AR ERBB2 KRT14 MDM2 PLAGL1 S100B
9 muscle MP:0005369 9.91 ACTC1 AR ERBB2 GFAP MDM2 MYOZ2
10 limbs/digits/tail MP:0005371 9.85 AR ERBB2 MDM2 PLAGL1 TP53 TP63
11 neoplasm MP:0002006 9.63 AR ERBB2 KRT14 MDM2 TP53 TP63
12 normal MP:0002873 9.61 ACTC1 AR ERBB2 GFAP MDM2 S100B
13 reproductive system MP:0005389 9.23 AR ERBB2 KRT14 MDM2 PLAG1 TP53

Drugs & Therapeutics for Pleomorphic Adenoma

Drugs for Pleomorphic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
5
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
6
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
7
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
8
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
9
Doxil Approved June 1999 Phase 2, Phase 3 31703
10 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
11 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
12 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
13 Antineoplastic Agents, Alkylating Phase 3,Phase 2
14 Alkylating Agents Phase 3,Phase 2
15
Isophosphamide mustard Phase 3,Phase 2 0
16 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
17
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
18
Mesna Approved, Investigational Phase 2 3375-50-6 598
19
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
20
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
21
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
22
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
23
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
25
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
26
Ipilimumab Approved Phase 2 477202-00-9
27
nivolumab Approved Phase 2 946414-94-4
28
Olaparib Approved Phase 2,Phase 1 763113-22-0 23725625
29
Durvalumab Approved, Investigational Phase 2 1428935-60-7
30
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
31
Metformin Approved Phase 2 657-24-9 14219 4091
32
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
33
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
34
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
35
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
36
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
37
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
38
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
39
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
40
Iniparib Investigational Phase 2 160003-66-7
41
Saracatinib Investigational Phase 2 379231-04-6
42
Cediranib Investigational Phase 2 288383-20-0 9933475
43
Tremelimumab Investigational Phase 2 745013-59-6
44
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
45
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
46
Entinostat Investigational Phase 1, Phase 2 209783-80-2
47 Antiviral Agents Phase 2
48 Immunosuppressive Agents Phase 2,Phase 1
49 Immunologic Factors Phase 2,Phase 1
50 Anti-Infective Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
4 Quadrant Versus Superficial Parotidectomy Withdrawn NCT01607866 Phase 2, Phase 3
5 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
6 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
7 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
8 Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours Completed NCT00189410 Phase 2 Pegylated Liposomal Doxorubicin and Carboplatin
9 Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
10 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
11 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
12 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
13 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
14 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
15 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
16 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
17 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
18 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
19 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
20 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
21 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
22 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
23 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
24 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
25 Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting NCT03458728 Phase 1, Phase 2 BAY806946
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
28 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
29 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
30 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
31 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
32 LN-145 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine Phosphate
33 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
34 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
35 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
36 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
37 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
38 Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy Not yet recruiting NCT03933761 Phase 2 Pamiparib
39 Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Not yet recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
40 Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Terminated NCT00322881 Phase 2 Paclitaxel;Carboplatin
41 Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy Terminated NCT00505492 Phase 2 Carboplatin;Cisplatin;Paclitaxel
42 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
43 Vorinostat (SAHA) in Uterine Sarcoma Terminated NCT03509207 Phase 2 Vorinostat Oral Capsule
44 Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Withdrawn NCT00984217 Phase 2 Panitumumab
45 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1 Lapatinib and ixempra
46 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1 belinostat;5-Fluorouracil (5-FU)
47 Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00413075 Phase 1 oral belinostat
48 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
49 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
50 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin

Search NIH Clinical Center for Pleomorphic Adenoma

Cochrane evidence based reviews: adenoma, pleomorphic

Genetic Tests for Pleomorphic Adenoma

Anatomical Context for Pleomorphic Adenoma

MalaCards organs/tissues related to Pleomorphic Adenoma:

42
Salivary Gland, Bone, Uterus, Trachea, Prostate, Tongue, Ovary

The Foundational Model of Anatomy Ontology organs/tissues related to Pleomorphic Adenoma:

20
The Salivary Gl

Publications for Pleomorphic Adenoma

Articles related to Pleomorphic Adenoma:

(show top 50) (show all 1514)
# Title Authors Year
1
Giant De Novo Pleomorphic Adenoma of Parapharyngeal Space, Can It Cause Spinal Deformity? A Case Report. ( 31053323 )
2019
2
Dysregulated long non‑coding RNAs in pleomorphic adenoma tissues of pleomorphic adenoma gene 1 transgenic mice. ( 31059011 )
2019
3
Nodular Fasciitis Mimicking Pleomorphic Adenoma. ( 31064246 )
2019
4
Metastatic Pleomorphic Adenoma in the infratemporal fossa and neck following total parotidectomy after 30 years. ( 31079134 )
2019
5
Magnetic Resonance Imaging and Histopathology in a Case of Pleomorphic Adenoma of a Minor Salivary Gland in the Nasal Cavity. ( 31079138 )
2019
6
Pleomorphic Adenoma of the Submandibular Gland: A Case Report. ( 31080247 )
2019
7
Metastasizing Pleomorphic Adenoma: Recurrent PLAG1/HMGA2 Rearrangements and Identification of a Novel HMGA2-TMTC2 Fusion. ( 31094927 )
2019
8
Ossified Carcinoma Ex Pleomorphic Adenoma in accessory lobe of parotid gland: Complexity in clinical, imaging and histologic diagnosis and minimally invasive surgery. ( 30853278 )
2019
9
Recurrent benign pleomorphic adenoma of the parotid gland: Facial nerve identification and risk factors for facial nerve paralysis at re-operation. ( 30922530 )
2019
10
Coblator-Assisted Endoscopic Transnasal Resection of a Large Nasopharyngeal Pleomorphic Adenoma. ( 30937204 )
2019
11
Effective chemotherapy for submandibular gland carcinoma ex pleomorphic adenoma with lung metastasis after radiotherapy: A case report. ( 30968046 )
2019
12
Schwannoma-Like Pleomorphic Adenoma: Two Cases and a Review of the Literature. ( 30968284 )
2019
13
Anti-N-Methyl-D-Aspartate Receptor Encephalitis in a Patient With Antithyroid Peroxidase Antibodies and a Parotid Pleomorphic Adenoma. ( 30983904 )
2019
14
Pleomorphic Adenoma of the Trachea. ( 30987459 )
2019
15
Primary Pleomorphic Lipoma of the Parotid Gland with Prominent Myxoid Change: Report of a Rare Case Mimicking Carcinoma Ex Pleomorphic Adenoma on Fine Needle Aspiration Cytology. ( 30610525 )
2019
16
'Pleomorphic adenoma of the tongue: A common entity at the uncommon location'. ( 30619605 )
2019
17
Lacrimal gland pleomorphic adenoma: a review of 52 cases, 15-year experience. ( 30628498 )
2019
18
Potential immmunohistochemical markers to characterize epithelial-mesenchymal transition in pleomorphic adenoma. ( 30658020 )
2019
19
Ectopic pleomorphic adenoma on subcutaneous plane of the cheek. ( 30703863 )
2019
20
Intraductal pseudopodia in pleomorphic adenoma of parotid gland. ( 30706873 )
2019
21
Extracapsular invasion: A potential prognostic marker for Carcinoma ex-pleomorphic adenoma of the salivary glands? A Systematic Review. ( 30756461 )
2019
22
Collagenous crystalloids in pleomorphic adenoma of the parotid gland. ( 30756515 )
2019
23
Parapharyngeal Space Venous Malformation: An Imaging Mimic of Pleomorphic Adenoma. ( 30409847 )
2019
24
Technique of the Buccal Fat Pad Flap as an Alternative for the Surgical Defect of Pleomorphic Adenoma. ( 30418286 )
2019
25
The role of adjuvant radiotherapy in management of recurrent pleomorphic adenoma of the parotid gland: a systematic review. ( 30426229 )
2019
26
Spindle cell lipoma mimicking pleomorphic adenoma: A diagnostic challenge on cytology. ( 30468314 )
2019
27
A comparison of conventional and diffusion-weighted magnetic resonance imaging in the diagnosis of sialadenitis and pleomorphic adenoma. ( 30497909 )
2019
28
Pleomorphic adenoma of the mandibular salivary gland in a captive African pygmy hedgehog (Atelerix albiventris). ( 30531130 )
2019
29
Sinonasal pleomorphic adenoma: A single institution case series combined with a comprehensive review of literatures. ( 30122650 )
2019
30
Clinicopathological effect of PLAG1 fusion genes in pleomorphic adenoma and carcinoma ex pleomorphic adenoma with special emphasis on histological features. ( 30307055 )
2019
31
Lacrimal gland pleomorphic adenoma and malignant epithelial tumours: clinical and imaging differences. ( 29680804 )
2019
32
Dedifferentiated adenoid cystic carcinoma ex pleomorphic adenoma of the parotid. ( 29893347 )
2018
33
The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. ( 29266837 )
2018
34
Heterotopic pleomorphic adenoma in the postauricular area. ( 30895136 )
2018
35
Human epithelial growth factor receptor 2 in human salivary carcinoma ex pleomorphic adenoma: a potential therapeutic target. ( 30555262 )
2018
36
Pleomorphic adenoma of the epiglottis. ( 30591211 )
2018
37
Fatty acid synthase (FASN) and Ki-67 immunoexpression can be useful for the identification of malignant component in carcinoma ex-pleomorphic adenoma. ( 30597641 )
2018
38
An Unusual Variant of a Common Palatal Salivary Gland Tumor: Case Report of a Pleomorphic Adenoma with Significant Lipomatous Metaplasia. ( 30675402 )
2018
39
Trastuzumab-Based Combination Chemotherapy in Patients with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma. ( 30687059 )
2018
40
Nasopharyngeal Pleomorphic Adenoma: A Rare Case Report and Review of the Literature. ( 30693126 )
2018
41
Two case reports of synchronous unilateral pleomorphic adenoma and cystadenolymphoma of the parotid gland with literature review. ( 30763025 )
2018
42
Pleomorphic Adenoma of the Upper Lip: A Case Report. ( 30787814 )
2018
43
Right main bronchial pleomorphic adenoma: A case report and literature review. ( 30334948 )
2018
44
Pleomorphic adenoma of the head and neck in children: presentation and management. ( 30431646 )
2018
45
Acantholytic Squamous Cell Carcinoma and Salivary Duct Carcinoma Ex-pleomorphic Adenoma of the Submandibular Gland: A Report of Two Extremely Rare Cases with an Immunohistochemical Analysis. ( 30484070 )
2018
46
Diagnosis of an extremely rare pleomorphic adenoma of the breast with core needle biopsy: A case report. ( 30510762 )
2018
47
A rare ectopic localization of pleomorphic adenoma. ( 30513390 )
2018
48
Oncocytic cystadenoma and oncocytic cysts of the parotid gland occurring synchronously with a pleomorphic adenoma. ( 30522841 )
2018
49
Age and adenoma size are independent risk factors for the development of carcinoma ex pleomorphic adenoma. ( 30115468 )
2018
50
Identifying Candidate Biomarkers for Pleomorphic Adenoma: A Case-Control Study. ( 30120721 )
2018

Variations for Pleomorphic Adenoma

Cosmic variations for Pleomorphic Adenoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43909 TP53 salivary gland,parotid,adenoma,pleomorphic c.817C>A p.R273S 17:7673803-7673803 0
2 COSM6932 TP53 salivary gland,parotid,adenoma,myoepithelial c.733G>A p.G245S 17:7674230-7674230 0
3 COSM43635 TP53 salivary gland,parotid,adenoma,myoepithelial c.536A>T p.H179L 17:7675076-7675076 0
4 COSM10808 TP53 salivary gland,parotid,adenoma,pleomorphic c.488A>G p.Y163C 17:7675124-7675124 0
5 COSM13168 CTNNB1 salivary gland,parotid,adenoma,NS c.104T>C p.I35T 3:41224616-41224616 0
6 COSM5688 CTNNB1 salivary gland,parotid,adenoma,NS c.121A>C p.T41P 3:41224633-41224633 0
7 COSM21826 ATM salivary gland,parotid,adenoma,NS c.2572T>C p.F858L 11:108267276-108267276 0

Copy number variations for Pleomorphic Adenoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 239266 8 38279166 38315052 Gain FGFR1 Pleomorphic adenoma

Expression for Pleomorphic Adenoma

Search GEO for disease gene expression data for Pleomorphic Adenoma.

Pathways for Pleomorphic Adenoma

GO Terms for Pleomorphic Adenoma

Cellular components related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.97 ACTC1 AR ERBB2 GFAP KRT14 MDM2
2 nucleus GO:0005634 9.44 AR ERBB2 HMGA2 KRT14 MDM2 MUC1
3 nuclear chromatin GO:0000790 9.26 AR MUC1 TP53 TP63

Biological processes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 negative regulation of apoptotic process GO:0043066 9.81 ACTC1 HMGA2 MDM2 TP53
3 cellular response to hypoxia GO:0071456 9.75 MDM2 S100B TP53
4 cell proliferation GO:0008283 9.72 AR ERBB2 S100B TP53 TP63
5 regulation of signal transduction by p53 class mediator GO:1901796 9.65 MDM2 TP53 TP63
6 negative regulation of neuron projection development GO:0010977 9.61 GFAP MDM2 VIM
7 intermediate filament organization GO:0045109 9.57 GFAP VIM
8 astrocyte development GO:0014002 9.56 GFAP VIM
9 positive regulation of glial cell proliferation GO:0060252 9.55 GFAP PLAG1
10 prostate gland development GO:0030850 9.54 AR TP63
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.52 MUC1 TP53
12 Bergmann glial cell differentiation GO:0060020 9.46 GFAP VIM
13 prostate gland growth GO:0060736 9.4 AR PLAG1
14 cellular response to actinomycin D GO:0072717 9.26 MDM2 TP53
15 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.26 MDM2 MUC1 PLAGL1 TP53
16 positive regulation of gene expression GO:0010628 9.23 ACTC1 AR ERBB2 HMGA2 MDM2 PLAG1
17 positive regulation of transcription by RNA polymerase III GO:0045945 9.19 AR
18 intermediate filament-based process GO:0045103 9.16 GFAP VIM

Molecular functions related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.91 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.65 AR HMGA2 MUC1 PLAG1 TP53
3 transcription regulatory region DNA binding GO:0044212 9.62 AR HMGA2 TP53 TP63
4 structural constituent of cytoskeleton GO:0005200 9.58 GFAP KRT14 VIM
5 identical protein binding GO:0042802 9.5 ERBB2 GFAP MDM2 S100B TP53 TP63
6 keratin filament binding GO:1990254 9.16 KRT14 VIM
7 p53 binding GO:0002039 8.92 MDM2 MUC1 TP53 TP63

Sources for Pleomorphic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....